Verastem Stock Based Compensation vs Change In Cash Analysis
VSTM Stock | USD 4.19 0.25 5.63% |
Verastem financial indicator trend analysis is much more than just breaking down Verastem prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Verastem is a good investment. Please check the relationship between Verastem Stock Based Compensation and its Change In Cash accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.
Stock Based Compensation vs Change In Cash
Stock Based Compensation vs Change In Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Verastem Stock Based Compensation account and Change In Cash. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Verastem's Stock Based Compensation and Change In Cash is -0.33. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Verastem, assuming nothing else is changed. The correlation between historical values of Verastem's Stock Based Compensation and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Verastem are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Stock Based Compensation i.e., Verastem's Stock Based Compensation and Change In Cash go up and down completely randomly.
Correlation Coefficient | -0.33 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Change In Cash
Most indicators from Verastem's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Verastem current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.At this time, Verastem's Selling General Administrative is very stable compared to the past year. As of the 22nd of December 2024, Issuance Of Capital Stock is likely to grow to about 125.5 M, while Sales General And Administrative To Revenue is likely to drop 2.31.
Verastem fundamental ratios Correlations
Click cells to compare fundamentals
Verastem Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Verastem fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 145.0M | 154.3M | 108.7M | 95.1M | 149.7M | 125.4M | |
Other Current Liab | 450K | 14.1M | 15.0M | 15.0M | 17.3M | 9.1M | |
Total Current Liabilities | 29.9M | 17.1M | 18.6M | 21.7M | 26.4M | 16.6M | |
Total Stockholder Equity | 7.2M | 115.3M | 87.6M | 47.4M | 57.4M | 75.3M | |
Accounts Payable | 9.7M | 1.9M | 2.3M | 4.9M | 7.2M | 5.0M | |
Cash | 43.5M | 67.8M | 100.3M | 74.9M | 78.8M | 63.4M | |
Common Stock Shares Outstanding | 6.2M | 12.8M | 14.5M | 16.1M | 22.1M | 23.2M | |
Other Current Assets | 3.8M | 6.9M | 5.0M | 4.9M | 6.6M | 6.9M | |
Total Liab | 137.9M | 39.1M | 21.1M | 47.7M | 71.2M | 48.4M | |
Common Stock | 7K | 8K | 17K | 19K | 20K | 2.9K | |
Property Plant Equipment | 947K | 3.1M | 210K | 92K | 105.8K | 100.5K | |
Property Plant And Equipment Net | 4.0M | 3.1M | 210K | 1.9M | 1.2M | 1.8M | |
Net Debt | 64.0M | (45.2M) | (98.0M) | (47.9M) | (36.4M) | (38.2M) | |
Retained Earnings | (524.8M) | (592.5M) | (663.7M) | (737.5M) | (824.9M) | (783.6M) | |
Non Current Assets Total | 60.1M | 9.4M | 2.9M | 2.2M | 6.0M | 11.4M | |
Non Currrent Assets Other | 36.1M | 274K | 2.5M | 58K | 4.6M | 4.2M | |
Other Assets | 36.1M | 9.0M | 410K | 299K | 343.9K | 326.7K | |
Cash And Short Term Investments | 75.5M | 141.2M | 100.3M | 87.9M | 137.1M | 115.7M | |
Common Stock Total Equity | 8K | 17K | 19K | 20K | 23K | 24.2K | |
Short Term Investments | 32.0M | 73.4M | 79.0M | 13.0M | 59.2M | 61.7M | |
Liabilities And Stockholders Equity | 145.0M | 154.3M | 108.7M | 95.1M | 149.7M | 134.7M | |
Non Current Liabilities Total | 108.0M | 22.0M | 2.5M | 26.0M | 44.8M | 34.2M | |
Other Stockholder Equity | 531.9M | 707.7M | 751.2M | 784.9M | 861.1M | 468.2M | |
Property Plant And Equipment Gross | 4.0M | 416K | 4.2M | 3.4M | 2.8M | 2.2M | |
Total Current Assets | 85.0M | 144.9M | 105.7M | 92.9M | 143.7M | 119.1M | |
Accumulated Other Comprehensive Income | 14K | 53K | 34K | 13K | 15.0K | 15.7K | |
Net Tangible Assets | (12.8M) | 115.3M | 87.6M | 47.4M | 42.7M | 63.3M | |
Long Term Debt | 103.6M | 19.1M | 249K | 24.5M | 40.1M | 29.1M | |
Net Receivables | 2.5M | 239K | 516K | 31K | 42K | 39.9K | |
Retained Earnings Total Equity | (524.8M) | (592.5M) | (663.7M) | (737.5M) | (663.8M) | (630.6M) | |
Capital Surpluse | 531.9M | 707.7M | 751.2M | 784.9M | 902.6M | 481.7M | |
Non Current Liabilities Other | 4.4M | 2.9M | 2.3M | 1.5M | 1.7M | 1.4M | |
Short Long Term Debt Total | 107.5M | 22.5M | 2.3M | 27.1M | 41.6M | 38.4M | |
Long Term Debt Total | 103.6M | 19.1M | 249K | 24.5M | 22.1M | 36.9M | |
Net Invested Capital | 110.8M | 134.3M | 87.8M | 72.2M | 97.5M | 93.7M | |
Net Working Capital | 55.1M | 127.8M | 87.2M | 71.2M | 117.3M | 85.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share 0.331 | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (1.37) |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.